Bacterin picks new CEO; Medtronic launches MRI-safe pain tech;

@FierceMedDev: Navidea's losses widen as it waits for Lymphoseek to catch on. Article | Follow @FierceMedDev

@DamianFierce: Israel's Given Imaging had a record Q2 and believes better things are on the horizon. Report | Follow @DamianFierce

> Bacterin ($BONE) swung to a net loss of $2.5 million last quarter despite a slight uptick in revenue, but Dan Goldberger, the company's newly appointed CEO, said the implant producer is on track for future growth. Results | CEO appointment

> Tryton Medical is kicking off a physician education program to expand the adoption of its stent for bifurcation lesions. More

> Fresh off its $54 million IPO, NanoString ($NSTG) is expecting between $29.5 million and $31.5 million in revenue for 2013, good for up to 37% growth. Financials

> Singapore's Biosensors watched its revenue slip more than 11% to $76.7 million last quarter, a decline the company blames on a drop in royalty and licensing dollars. Item

> Alabama's Diatherix Laboratories has acquired the patent to a multipurpose diagnostic technology from Qiagen ($QGEN). News

> Medtronic ($MDT) has launched an MRI-safe version of its RestoreSensor neurostimulation system, a device designed to treat chronic pain. Release

Biotech News

@FierceBiotech: Report: Seattle biotech VLST unloads assets and shuts doors. More | Follow @FierceBiotech

@JohnCFierce: Acceleron pitches $75M IPO as Celgene pushes partnership through PhII. News | Follow @JohnCFierce

@RyanMFierce: Now that "microbiome" means something to people... NuMe Health changes name to MicroBiome Therapeutics. Release | Follow @RyanMFierce

> Vaxart garners $20M VC round for vaccine pills. Item

> Report: Determined Amgen sweetens its bid for Onyx Pharma. Story

> FDA experts give Bayer's riociguat unanimous backing for lung disease. Article

Pharma News

@FiercePharma: Looking for a sales job? Lundbeck to hire > 200 to market antidepressant Brintellix, in prep for FDA nod. More | Follow @FiercePharma

@CarlyHFierce: In Vivus earnings, not a lot of revenue, but analysts seem optimistic about Zook's plans for Qsymia. Release | Follow @CarlyHFierce

> Novartis' ambitions for Afinitor suffer on liver-cancer failure. More

> Valeant CEO: Merger of equals still on the table. Story

> China revokes patent on Gilead's Viread. Article

Biomarkers News

> Biomarker IDs cancer patients most likely to respond to EGFR inhibitors. Item

> NIH pushes for biomarker research to catch up with needs of kids. Story

> Are cancer biomarker tests grossly underused? More

> Elevated carbon monoxide levels in breath can point to infection. Story

> Broad, Dana-Farber license lung cancer biomarker IP to MolecularMD. Article

> Altered enzyme indicates Alzheimer's-like dementia. Item

Drug Delivery News

@MichaelGFierce: "Soft robotic" hydrogel arms show drug delivering capability. More | Follow @MichaelGFierce

> UCSD surgeons deliver cancer drugs to brain with ClearPoint MRI tech. Story

> 3M sells dry powder inhaler rights to Adamis. News

> Next-gen Alzheimer's drug targets brain enzyme. Story

> Ocular Therapeutix nets FDA panel meeting for eye surgery hydrogel. Item

> Halozyme regrouping after ViroPharma trial flop. Article